Cargando…

Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis

BACKGROUND: Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some patients treated with nintedanib experience weight loss. Exploratory data suggest that low body mass index or weight loss are associated with worse outcomes in patients with IPF. We investigated whether BMI a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jouneau, Stéphane, Crestani, Bruno, Thibault, Ronan, Lederlin, Mathieu, Vernhet, Laurent, Valenzuela, Claudia, Wijsenbeek, Marlies, Kreuter, Michael, Stansen, Wibke, Quaresma, Manuel, Cottin, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690188/ https://www.ncbi.nlm.nih.gov/pubmed/33239000 http://dx.doi.org/10.1186/s12931-020-01528-4

Ejemplares similares

Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON
por: Song, Jin Woo, et al.
Publicado: (2019)

Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial
por: Noth, Imre, et al.
Publicado: (2021)

Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials
por: Costabel, Ulrich, et al.
Publicado: (2018)

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
por: Glaspole, Ian, et al.
Publicado: (2021)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

Soluble CD163 is produced by monocyte-derived and alveolar macrophages, and is not associated with the severity of idiopathic pulmonary fibrosis
por: Chauvin, Pierre, et al.
Publicado: (2022)

Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
por: Kreuter, Michael, et al.
Publicado: (2023)

Cough in idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2016)

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2020)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
por: Richeldi, Luca, et al.
Publicado: (2023)

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2022)

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
por: Wuyts, Wim A., et al.
Publicado: (2016)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
por: Wijsenbeek, Marlies S., et al.
Publicado: (2022)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
por: Moor, Catharina C., et al.
Publicado: (2017)

The world of rare interstitial lung diseases
por: Buschulte, Katharina, et al.
Publicado: (2023)

Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials
por: Swigris, Jeffrey J, et al.
Publicado: (2018)

Idiopathic pulmonary fibrosis diagnosed concomitantly with diffuse squamous cell lung cancer on surgical lung biopsy: a case report
por: Niel, C., et al.
Publicado: (2021)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

The use of online visual analogue scales in idiopathic pulmonary fibrosis
por: Moor, Catharina C., et al.
Publicado: (2022)

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
por: Richeldi, Luca, et al.
Publicado: (2018)

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
por: Santermans, Eva, et al.
Publicado: (2019)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Where are the gaps in education in the field of rare lung disease? Perspectives from the ERN-LUNG educational programme survey
por: Powell, Pippa, et al.
Publicado: (2019)

Physiology of the lung in idiopathic pulmonary fibrosis
por: Plantier, Laurent, et al.
Publicado: (2018)

Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE
por: Nakshbandi, Gizal, et al.
Publicado: (2023)

Interstitial Lung Disease and Mediastinal Lymph Nodes: A Computed Tomography–based Biomarker beyond Nosological and Etiological Borders?
por: Lescoat, Alain, et al.
Publicado: (2019)

A case report of Covid-19 in an autoimmune pulmonary alveolar proteinosis: An association in tune with the times!
por: Coirier, Valentin, et al.
Publicado: (2023)

Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
por: Valenzuela, Claudia, et al.
Publicado: (2020)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
por: Maher, Toby M, et al.
Publicado: (2023)

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
por: Maher, Toby M, et al.
Publicado: (2019)

Editorial: Interstitial Lung Disease Around the World
por: Wijsenbeek, Marlies, et al.
Publicado: (2022)

The flare of care for rare: per aspera ad astra for rare lung diseases!
por: Wijsenbeek, Marlies, et al.
Publicado: (2023)

Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World
por: Polke, Markus, et al.
Publicado: (2021)

Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2019)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Role of serum immunoglobulins for predicting sarcoidosis outcome: A cohort study
por: Belhomme, Nicolas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ano9qhsr6umads2a0rok8etdj9